Scientists Uncover Key Mechanism Behind Tau Protein Buildup in Alzheimer's

UCLA Health and UCSF researchers identify a protein complex that marks tau for degradation, offering new therapeutic targets.

Jan. 30, 2026 at 5:31am by Ben Kaplan

Got story updates? Submit your updates here. ›

New research has uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer's disease and related dementias. Using a novel CRISPR-based genetic screening approach on lab-grown human brain cells, the study identified a protein complex called CRL5SOCS4 that marks tau protein for degradation, suggesting that strengthening this natural defense mechanism could represent a new therapeutic strategy.

Why it matters

Tau protein buildup and aggregation is a key driver of neurodegeneration in Alzheimer's and other dementias, but researchers had not fully understood why some neurons are more vulnerable to tau toxicity than others. This study provides important insights into the cellular mechanisms that control tau levels, which could lead to new treatments targeting the root causes of these devastating diseases.

The details

The researchers used CRISPR gene-editing technology in neurons derived from human stem cells to systematically test how knocking down individual genes affected the buildup of toxic tau clumps. Among more than 1,000 genes identified, the CRL5SOCS4 protein complex emerged as a key player that attaches molecular tags to tau, marking it for destruction by the cell's recycling machinery. The study also revealed an unexpected connection between mitochondrial dysfunction and the production of a specific tau fragment that may influence disease progression.

  • The study was published in the journal Cell on January 30, 2026.

The players

UCLA Health

A leading academic medical center and part of the University of California system, known for its innovative research and patient care.

UC San Francisco

A top-ranked public university focused on health sciences, with a strong reputation in biomedical research.

Dr. Avi Samelson

Assistant professor of Neurology at UCLA Health, who conducted the research while at UCSF.

CRL5SOCS4

A protein complex that the study found marks tau protein for degradation, potentially offering a new therapeutic target for Alzheimer's and other neurodegenerative diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We wanted to understand why some neurons are vulnerable to tau accumulation while others are more resilient. By systematically screening nearly every gene in the human genome, we found both expected pathways and completely unexpected ones that control tau levels in neurons.”

— Dr. Avi Samelson, Assistant professor of Neurology at UCLA Health (Mirage News)

“What makes this study particularly valuable is that we used human neurons carrying an actual disease-causing mutation. These cells naturally have differences in tau processing, giving us confidence that the mechanisms we identified are relevant to human disease.”

— Dr. Avi Samelson, Assistant professor of Neurology at UCLA Health (Mirage News)

What’s next

The researchers emphasized that translating these discoveries into treatments will require additional research, but the findings provide several promising leads for therapeutic development, such as enhancing CRL5SOCS4 activity to help neurons clear tau more effectively or strategies to maintain proteasome function during stress to prevent the formation of toxic tau fragments.

The takeaway

This study offers important insights into the cellular mechanisms controlling tau protein levels, a key driver of neurodegeneration in Alzheimer's and other dementias. By identifying unexpected pathways that regulate tau, the findings open up new avenues for developing much-needed treatments targeting the root causes of these devastating diseases.